Draft Genome Sequences of Two Cystic Fibrosis Strains of *Stenotrophomonas maltophilia*, AU30115 and AU32848

Korin Eckstrom,a Graham G. Willsey,a John J. LiPuma,b Matthew J. Wargoa

aDepartment of Microbiology and Molecular Genetics, University of Vermont Larner College of Medicine, Burlington, Vermont, USA
bDepartment of Pediatrics and Communicable Disease, University of Michigan Medical School, Ann Arbor, Michigan, USA

ABSTRACT *Stenotrophomonas maltophilia* is an opportunistic pathogen causing airway infection in people with cystic fibrosis (CF). Here, we report the draft genome sequences of two *S. maltophilia* strains, AU30115 and AU32848, recovered from CF patients.

*Stenotrophomonas maltophilia* infects between 3% and 15% of cystic fibrosis (CF) patients, and based on recent epidemiologic assessments, it is increasing in prevalence in this population (1–3). Infection of airways by *S. maltophilia* has been linked to poor outcomes, including decreased time to exacerbation, increased risk of death or transplant, CF-related diabetes, and decreased lung function (1–14). While *S. maltophilia* infection has not been proven to be causative for these outcomes, it can promote lung inflammation (15, 16) and is inherently multidrug resistant (9, 17). Despite its prevalence and clinical correlations, our understanding of *S. maltophilia* virulence and response to host defenses lags far behind that of other CF pathogens. Here, we report the draft genome sequences of two clinical strains of *S. maltophilia*. *S. maltophilia* AU30115 was recovered from an adult CF patient in Texas in 2014, and *S. maltophilia* AU32848 was recovered from an adult CF patient in Nebraska in 2015. Genomic DNA was purified from LB-grown cultures via cetyltrimethylammonium bromide (CTAB) extraction (18), assessed for integrity with a Bioanalyzer, and quantified using a Qubit fluorometer.

The genome sequencing of strains AU30115 and AU32848 was performed by the Vermont Integrative Genomics Resource (VIGR). Two separate runs of an Illumina HiSeq 1500 system were performed using Nextera library preparation, a 150-bp single end and an 85-bp single end in rapid run mode. Sequences were trimmed of adaptors and low-quality bases (<Q30) using Trim Galore v. 0.5.0 (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/), and quality was assessed using FastQC v. 0.11.6 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) prior to assembly. Trimmed reads from each run were combined into a single file per isolate containing 1,592,793 and 1,813,244 reads in AU30115 and AU32848, respectively. Assembly was performed using Unicycler v. 0.4.6 (19) with default parameters, including read error correction and assembly polishing. Assembly graphs were visualized and compared to the reference sequence using Bandage (20). Contigs with no match to the reference were queried against the NCBI nonredundant (nr) database and removed if they were found to be the result of eukaryotic or reagent contamination. Contigs shorter than 200 bp were also removed. After these removals, N50 values of 94,013 and 63,013 bp were obtained for AU30115 and AU32848, respectively. Closest genomic neighbors and nucleotide identities were determined using the Microbial Genomes Atlas (MiGA) (21) to query available genomes in the NCBI prokaryotic genome database.

The assembly of AU30115 resulted in 89 contigs at 41× coverage (total bases/
coverage, a total genome size of 4,383,122 bp, and a GC content of 66.64%. The closest coverage, a total genome size of 4,383,122 bp, and a GC content of 66.64%. The closest

**Data availability.** This whole-genome shotgun project has been deposited in GenBank under the accession no. GCF_003385015 and GCA_003385135, BioProject no. PRJNA483996, and SRA study no. SRP158885. The versions described in this paper are the first versions, GCA_003385015.1 and GCA_003385135.1.

**ACKNOWLEDGMENTS**

Sequencing was conducted at the Vermont Integrative Genomics Resource at the University of Vermont.

This study was supported by a Cystic Fibrosis Foundation pilot award and a University of Vermont Larner College of Medicine Internal Grants Program award to M.J.W. Additional support was provided by a Cystic Fibrosis Foundation grant to J.J.L. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**REFERENCES**

1. Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, Morgan W, Rosenfeld M, Group ES. 2015. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol 50:763–770. https://doi.org/10.1002/ppul.23217.

2. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL. 2010. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 45:363–370. https://doi.org/10.1002/ppul.21198.

3. Salsgiver EL, Fink AK, Knapp EA, LiPuma JJ, Olivier KN, Marshall BC, Saiman L. 2016. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. Chest 149:390–400. https://doi.org/10.1378/chest.15-0676.

4. Waters V, Atenuaf EG, Lu A, Yau Y, Tullis E, Ratjen F. 2013. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 12:482–486. https://doi.org/10.1016/j.jcf.2012.12.006.

5. Waters V, Atenuaf EG, Salazar JG, Lu A, Yau Y, Matukas L, Tullis E, Ratjen F. 2012. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros 11:8–13. https://doi.org/10.1016/j.jcf.2011.07.008.

6. Dalboge CS, Hansen CR, Pressler T, Hoiby N, Johansen HK. 2011. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. J Cyst Fibros 10:318–325. https://doi.org/10.1016/j.jcf.2011.03.006.

7. Junge S, Görlich D, den Reijer M, Wiedemann B, Tümmler B, Ellemunter J, Graepel-Manika U, Staab O, Wolfschlagler B, Szczepanski R, Schuster A, Tegtmeyer F-K, Sutharsan S, Wald A, Nofer J-R, van Wamel W, Becker K, Peters G, Kuhl BC. 2016. Factors associated with worse lung function in cystic fibrosis patients with persistent Staphylococcus aureus. PLoS One 11:e0166220. https://doi.org/10.1371/journal.pone.0166220.

8. Wetlauffer J, Klingel M, Yau Y, Stanoevic S, Tullis E, Ratjen F, Waters V. 2017. Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients. J Cyst Fibros 16:58–63. https://doi.org/10.1016/j.jcf.2016.06.007.

9. Rutter WC, Burgess DR, Burgess DS. 2017. Increasing incidence of multidrug resistance among cystic fibrosis respiratory bacterial isolates. Microb Drug Resist 23:51–55. https://doi.org/10.1089/mdr.2016.0048.

10. Lehoux Dubois C, Boudreau V, Tremblay F, Lavoie A, Berthiaume Y, Rabasa-Lhoret R, Coriat A. 2017. Association between glucose intolerance and bacterial colonisation in an adult population with cystic fibrosis, emergence of Stenotrophomonas maltophilia. J Cyst Fibros https://doi.org/10.1016/j.jcf.2017.01.018.

11. Stanoevic S, Ratjen F, Stephens D, Lu A, Yau Y, Tullis E, Waters V. 2013. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros 12:575–583. https://doi.org/10.1016/j.jcf.2013.05.009.

12. Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW. 2004. Association between Stenotrophomonas maltophilia and function in cystic fibrosis. Thorax 59:955–959. https://doi.org/10.1136/thx.2003.017707.

13. Graff GR, Burns JL. 2002. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 121:1754–1760. https://doi.org/10.1378/chest.121.6.1754.

14. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. 2005. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 146:681–687. https://doi.org/10.1016/j.jpeds.2004.12.039.

15. Waters VJ, Gomez MI, Soong G, Amin S, Ernst RK, Prince A. 2007. Immunomimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect Immun 75:1697–1703. https://doi.org/10.1128/IAI.01469-06.

16. Bi Bonaventura G, Pompilio A, Zappacosta R, Petrucci F, Fiscarelli E, Rossi C, Piccolomini R. 2010. Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DNA/2 mice and implications for cystic fibrosis. Infect Immun 78:2466–2476. https://doi.org/10.1128/IAI.01391-09.

17. Ratjen A, Yau Y, Wetlauffer J, Matukas L, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V. 2015. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob Agents Chemoth 59:711–713. https://doi.org/10.1128/AAC.04123-14.

18. Wilson K. 2001. Preparation of genomic DNA from bacteria. Curr Protoc Mol Biol 56:2.4.1–2.4.5. https://doi.org/10.1002/0471142727.mb0204s56.
19. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol 13:e1005595. https://doi.org/10.1371/journal.pcbi.1005595.
20. Wick RR, Schultz MB, Zobel J, Holt KE. 2015. Bandage: interactive visualization of de novo genome assemblies. Bioinformatics 31:3350–3352. https://doi.org/10.1093/bioinformatics/btv383.
21. Rodriguez RL, Gunturu S, Harvey WT, Rossello-Mora R, Tiedje JM, Cole JR, Konstantinidis KT. 2018. The Microbial Genomes Atlas (MiGA) webserver: taxonomic and gene diversity analysis of Archaea and Bacteria at the whole genome level. Nucleic Acids Res 46:W282–W288. https://doi.org/10.1093/nar/gky467.
22. Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L, Lomsadze A, Pruitt KD, Borodovsky M, Ostell J. 2016. NCBI Prokaryotic Genome Annotation Pipeline. Nucleic Acids Res 44:6614–6624. https://doi.org/10.1093/nar/gkw569.